Preparation & evaluation of Topical Rosuvastatin & Melatonin vs placebo in Patients with Mild to Moderate Plaque Psoriasis

Preparation & evaluation of Topical Rosuvastatin & Melatonin vs placebo in Patients with Mild to Moderate Plaque Psoriasis? A Randomized Double-blinded Clinical Trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190810044500N16

Enrollment

Registered

2021-06-13

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Psoriasis

Interventions

Intervention 1: Intervention group: Patients will use 5% melatonin cream twice daily for 8 weeks. Intervention 2: Intervention group: Patients will use 5% rosuvastatin cream twice daily for 8 weeks. I

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients 18 years and older Less than 10% body surface area (BSA)

Exclusion criteria

Exclusion criteria: Pregnancy Sensitivity to cream components

Design outcomes

Primary

Measure	Time frame
Psoriasis Area Severity Index. Timepoint: Weeks 0, 4, 8. Method of measurement: Score 0_72.	—

Secondary

Measure	Time frame
Dermatological Sum Score (DSS). Timepoint: Weeks 0,4,8. Method of measurement: Based on a scale of 4 points (0: absent,1: mild, 2: moderate, 3: severe).;Dermatology Life Quality Index (DLQI). Timepoint: weeks 0,4,8. Method of measurement: Based on the questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Saghafi

Yazd University of Medical Sciences

F.saghafi@ssu.ac.ir+98 35 3820 3419

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026